摘要:
The present disclosure relates to Plinabulin solid state forms, Plinabulin salts including hydrochloride and solid state forms thereof, processes for preparation thereof and pharmaceutical compositions thereof.
摘要:
The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.
摘要:
The present invention is concerned with new polymorphic forms of flupirtine maleate, processes for preparing the new polymorphic forms, pharmaceutical compositions containing them, therapeutic uses thereof and methods of treatment employing them.
摘要:
The present invention relates to solid state forms of fosamprenavir calcium salt, process for preparing said solid state forms, and pharmaceutical compositions thereof.
摘要:
The present disclosure relates to crystalline Lorlatinib:Fumaric acid, solid state forms thereof, processes for preparation N thereof, pharmaceutical compositions and methods of use thereof.
摘要:
The present disclosure relates to Plinabulin solid state forms, Plinabulin salts including hydrochloride and solid state forms thereof, processes for preparation thereof and pharmaceutical compositions thereof.
摘要:
The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.
摘要:
New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.
摘要:
New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.
摘要:
New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.